Refractory eosinophilic pustular folliculitis treated with tofacitinib: a case series and literature review.

IF 3.7 4区医学 Q1 DERMATOLOGY

Clinical and Experimental Dermatology Pub Date : 2025-02-01 DOI:10.1093/ced/llaf053

Qin-Xiao Wang, Hai-Yang He, Ying-Luo Niu, Sheng Fang

{"title":"Refractory eosinophilic pustular folliculitis treated with tofacitinib: a case series and literature review.","authors":"Qin-Xiao Wang, Hai-Yang He, Ying-Luo Niu, Sheng Fang","doi":"10.1093/ced/llaf053","DOIUrl":null,"url":null,"abstract":"Objectives: Eosinophilic pustular folliculitis (EPF) is an uncommon skin condition that presents as follicular papules or pustules. The treatment of EPF is challenging due to the high relapse rates. This study aimed to evaluate the efficacy and safety of tofacitinib as a treatment for EPF.Methods: We presented 3 patients with refractory EPF who had been successfully treated with tofacitinib at our clinic and conducted a literature review using the PubMed database to gain further insight into this promising therapy.Results: Our patients were effectively treated with tofacitinib. To date, only three patients with EPF treated with Janus kinase (JAK) inhibitors have been reported and reviewed: one treated with tofacitinib and two with abrocitinib. Complete remission was observed in all the above patients, with no adverse events or relapses reported during an average follow-up period of 4.3 months.Conclusion: Tofacitinib may be an emerging alternative treatment option for EFP patients. Larger randomized controlled studies are needed to confirm these findings.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf053","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Eosinophilic pustular folliculitis (EPF) is an uncommon skin condition that presents as follicular papules or pustules. The treatment of EPF is challenging due to the high relapse rates. This study aimed to evaluate the efficacy and safety of tofacitinib as a treatment for EPF.

Methods: We presented 3 patients with refractory EPF who had been successfully treated with tofacitinib at our clinic and conducted a literature review using the PubMed database to gain further insight into this promising therapy.

Results: Our patients were effectively treated with tofacitinib. To date, only three patients with EPF treated with Janus kinase (JAK) inhibitors have been reported and reviewed: one treated with tofacitinib and two with abrocitinib. Complete remission was observed in all the above patients, with no adverse events or relapses reported during an average follow-up period of 4.3 months.

Conclusion: Tofacitinib may be an emerging alternative treatment option for EFP patients. Larger randomized controlled studies are needed to confirm these findings.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

2.40%

发文量

389

审稿时长

3-8 weeks

期刊介绍： Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.